Sugi Predict

Sugi Predict / Compounds / SCHEMBL2597962

SCHEMBL2597962

SCHEMBL2597962

Cc1cc(CC(=O)O)ccc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.50
▸ HPGD P15428 4/20 0.50
▸ HSD17B10 Q99714 4/20 0.50
▸ MAPT P10636 3/20 0.50
▸ GAA P10253 3/20 0.50
▸ TSHR P16473 3/20 0.50
▸ NFKB1 P19838 2/20 0.50
▸ TDP1 Q9NUW8 2/20 0.50
▸ RGS12 O14924 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ APEX1 P27695 1/20 0.50
▸ THPO P40225 1/20 0.50
▸ BLM P54132 1/20 0.50
▸ GNAI1 P63096 1/20 0.50
▸ PMP22 Q01453 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ SKP2 Q13309 1/20 0.50
▸ GABRP O00591 2/20 0.49
▸ GABRD O14764 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1492449 0.85 MAPT (0.50) KDM4EHPGDHSD17B10MAPTGAA
SCHEMBL22092973 0.85 SKP2 (0.50) KDM4EGAATSHRTDP1LMNA
SCHEMBL1000171 0.82 GAA (0.55) KDM4EHPGDHSD17B10MAPTGAA
SCHEMBL969589 0.82 HPGD (0.55) KDM4EHPGDHSD17B10MAPTGAA
SCHEMBL7282363 0.81 SKP2 (0.56) SKP2CA2
SCHEMBL30354606 0.81 KDM4E (0.50) KDM4EHPGDHSD17B10MAPTGAA
SCHEMBL2434720 0.81 GAA (0.50) KDM4EHPGDHSD17B10MAPTGAA
SCHEMBL4944685 0.81 KDM4E (0.50) KDM4EHPGDHSD17B10MAPTGAA
SCHEMBL29808980 0.81 GAA (0.50) KDM4EHPGDHSD17B10MAPTGAA
SCHEMBL3213276 0.80 ALDH1A1 (0.66) KDM4EHPGDHSD17B10MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3573972-B1 RORGAMMA MODULATORS AND USES THEREOF GENFIT (FR) 2026-01-14 — — EP disclosed
EP-3426246-B1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF NATIONAL HEALTH RES INST (TW) 2024-05-01 — — EP disclosed
CN-111777520-B Synthesis method of multi-substituted dimethylamino phenyl acetic acid compound 苏州爱玛特生物科技有限公司 2023-04-07 — — CN disclosed
US-11077115-B2 Rorgamma modulators and uses thereof GENFIT (FR) 2021-08-03 — — US disclosed
US-11077115-B2 Rorgamma modulators and uses thereof GENFIT (FR) 2021-08-03 — — US disclosed
US-11052092-B2 N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases GENFIT (FR) 2021-07-06 — — US disclosed
CN-111777520-A Synthesis method of multi-substituted dimethylamino phenyl acetic acid compound 苏州爱玛特生物科技有限公司 2020-10-16 — — CN disclosed
US-10544113-B2 Thiazolidinone compounds and use thereof NATIONAL HEALTH RESEARCH INSTITUTE (TW) 2020-01-28 — — US disclosed
EP-3426246-A1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF National Health Research Institutes (TW) 2019-01-16 — — EP disclosed
WO-2018138359-A1 RORGAMMA MODULATORS AND USES THEREOF GENFIT (FR) 2018-08-02 — — WO disclosed
EP-2101751-A1 BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS Glaxo Group Limited (GB) 2009-09-23 — — EP disclosed
EP-2081896-A1 BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS Glaxo Group Limited (GB) 2009-07-29 — — EP disclosed
US-20080167377-A1 Novel compounds GLAXO GROUP LIMITED (GB) 2008-07-10 — — US disclosed
WO-2008071736-A1 BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2008-06-19 — — WO disclosed
WO-2008061955-A1 BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2008-05-29 — — WO disclosed
EP-1189612-A4 VLA-4 INHIBITOR COMPOUNDS DAIICHI SEIYAKU CO (JP) 2005-02-16 — — EP disclosed
EP-1189612-A1 VLA-4 INHIBITOR COMPOUNDS Daiichi Pharmaceutical Co., Ltd. (JP) 2002-03-27 — — EP disclosed
WO-2001000206-A1 VLA-4 INHIBITOR COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-04 — — WO disclosed
US-5359076-A Cyclic aminophenylacetic acid derivatives, process for preparing the same and immune response modulator having the same as an effective ingredient KYORIN PHARMACEUTICAL CO., LTD. (JP) 1994-10-25 — — US disclosed
EP-0538477-A1 NOVEL CYCLIC AMINOPHENYLACETIC ACID DERIVATIVE, PRODUCTION THEREOF, AND IMMUNE RESPONSE MODULATOR CONTAINING THE SAME AS ACTIVE INGREDIENT KYORIN PHARMACEUTICAL CO., LTD. (JP) 1993-04-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167377-A1 Novel compounds F12, C1R, MRGPRX1 KDM4E 3061/4885HPGD 2744/4885HSD17B10 2621/4885
US-11052092-B2 N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases RORA, RORC, RORB KDM4E 1701/4885HPGD 1037/4885HSD17B10 2237/4885
US-10544113-B2 Thiazolidinone compounds and use thereof OPRL1, OPRD1, OPRK1 KDM4E 3848/4885HPGD 289/4885HSD17B10 285/4885
US-11077115-B2 Rorgamma modulators and uses thereof RORB, RORC, RORA KDM4E 2276/4885HPGD 1776/4885HSD17B10 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.